AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vir Biotechnology, Inc. Director's Dealing 2025

Nov 18, 2025

32538_dirs_2025-11-18_6b7d84ca-65d7-4080-8acb-69614d284e93.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vir Biotechnology, Inc. (VIR)
CIK: 0001706431
Period of Report: 2025-11-17

Reporting Person: O'Byrne Jason (EVP & Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-17	Common Stock	S	6799	$5.557	Disposed	110701	Direct

Footnotes

F1: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.

F2: Includes 2,500 shares of common stock acquired by the Reporting Person on May 30, 2025 pursuant to an employee stock purchase program.